Courtesy Kallyope Kallyope, a biotech startup working to map out the gut-brain axis, has raised $66 million. The series B round will help the company get some of its programs nearer to human clinical trials and continue research on the relationship between the gut and its microbes and the brain. The hope is that by investigating the gut-brain axis, researchers might be able to better treat certain metabolic conditions, like obesity, as well as neurologic conditions like Parkinson's disease.